← All trials
NCT05009082
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2022
- Primary completion
- Jul 31, 2027
- Completion date
- Jan 31, 2030
- First posted
- Aug 17, 2021
- Last posted
- Aug 17, 2021
- Enrollment
- 970
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AGO GermanyLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Kliniken Essen-Mitte, GermanyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.